Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation.

Drug design, development and therapy - 1 Jan 2014

He Jiao-Yu, Li Cheng, Wu Guo

Abstract excerpt

BACKGROUND: After the first epidemic wave from February through May 2013, the influenza A (H7N9) virus emerged and has followed a second epidemic wave since June 2013. As of June 27, 2014, the outbreak of H7N9 had caused 450 confirmed cases of human infection, with 165 deaths included. The case-f...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arginine
Share to Drug Discovery
Share to Influenza A Virus, H7N9 Subtype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Influenza, Human

Share to Lysine

Share to Molecular Docking Simulation

Share to Molecular Structure

Share to Oseltamivir

Source

Open in PubMed Open full text

Identifiers

PMID: 25489236
DOI: 10.2147/DDDT.S74061
PMCID: PMC4257025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25489236-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation.PMID 25489236Read ↗

Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.Semantic proximity Read ↗

In Silico Studies Reveal Peramivir and Zanamivir as an Optimal Drug Treatment Even If H7N9 Avian Type Influenza Virus Acquires Further Resistance.Semantic proximity Read ↗

Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity.Semantic proximity Read ↗

Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses.Semantic proximity Read ↗

Structural Investigations and Binding Mechanisms of Oseltamivir Drug Resistance Conferred by the E119V Mutation in Influenza H7N9 Virus.Semantic proximity Read ↗

Impact of the R292K Mutation on Influenza A (H7N9) Virus Resistance towards Peramivir: A Molecular Dynamics Perspective.Semantic proximity Read ↗

Computational analysis of the receptor binding specificity of novel influenza A/H7N9 viruses.Semantic proximity Read ↗

Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment.Semantic proximity Read ↗

Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitutionSemantic proximity Read ↗

In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivirSemantic proximity Read ↗

Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study.Semantic proximity Read ↗

Advanced simulations and screening to design a 3C protease inhibitor against the drug resistant human norovirus-induced gastroenteritisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.